1. Acute Stress Cardiomyopathy: Heart of pheochromocytoma
- Author
-
Emmanuelle Vidal-Petiot, Laurence Amar, Ines Belmihoub, Erika Cornu, Justina Motiejunaite, and Mariana Mirabel
- Subjects
medicine.medical_specialty ,Neurotransmitter uptake ,Endocrinology, Diabetes and Metabolism ,Adrenal Gland Neoplasms ,Cardiomyopathy ,030209 endocrinology & metabolism ,Pheochromocytoma ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Takotsubo Cardiomyopathy ,Internal medicine ,medicine ,Humans ,Heart Failure ,business.industry ,Cardiogenic shock ,fungi ,Heart ,General Medicine ,medicine.disease ,Pheochromocytoma crisis ,Pathophysiology ,Dopamine receptor ,030220 oncology & carcinogenesis ,Heart failure ,Cardiology ,Cardiomyopathies ,business ,Stress, Psychological - Abstract
Stress cardiomyopathy (SCM) is a syndrome characterized by transient regional systolic dysfunction of the left ventricle in the absence of angiographic evidence of coronaropathy. This abnormality is associated with high levels of catecholamines. Stress cardiomyopathy is also called Takotsubo (TS) cardiomyopathy. Pheochromocytoma crisis can occur spontaneously or can be precipitated by manipulation of the tumor, trauma, certain medications or stress for example during non-adrenal surgery. The main drugs leading to pheochromocytoma crisis include D2 dopamine receptor antagonists, noncardioselective β-adrenergic receptor blockers, tricyclic antidepressants and related neurotransmitter uptake blockers, sympathomimetics, certain peptide and steroid hormones and several agents used during induction of anesthesia. Patients can develop symptoms of heart failure associated with tachyarrhythmia, cardiogenic shock with hypotension and collapse, or apparent acute coronary syndromes. This review describes pathophysiology, epidemiology, diagnosis criteria and management of SCM.
- Published
- 2021